120 related articles for article (PubMed ID: 15346583)
1. Drug maker to pay $430 million in fines, civil damages.
FDA Consum; 2004; 38(4):36-7. PubMed ID: 15346583
[TBL] [Abstract][Full Text] [Related]
2. Doctor explains why he blew the whistle.
Petersen M
N Y Times Web; 2003 Mar; ():C1, C2. PubMed ID: 12812161
[No Abstract] [Full Text] [Related]
3. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
Kesselheim AS; Darby D; Studdert DM; Glynn R; Levin R; Avorn J
Health Aff (Millwood); 2011 Dec; 30(12):2318-27. PubMed ID: 22147859
[TBL] [Abstract][Full Text] [Related]
4. Gabapentin--a new antiepileptic drug.
Drug Ther Bull; 1994 Apr; 32(4):29-30. PubMed ID: 7635023
[TBL] [Abstract][Full Text] [Related]
5. Pfizer pleads guilty, but drug sales continue to soar.
Lenzer J
BMJ; 2004 May; 328(7450):1217. PubMed ID: 15155480
[No Abstract] [Full Text] [Related]
6. Warner-Lambert found guilty of promoting neurontin off label.
Larkin M
Lancet Neurol; 2004 Jul; 3(7):387. PubMed ID: 15228033
[No Abstract] [Full Text] [Related]
7. Court papers suggest scale of drug's use: lawsuit says doctors were paid endorsers.
Petersen M
N Y Times Web; 2003 May; ():C1, C2. PubMed ID: 12812176
[No Abstract] [Full Text] [Related]
8. FDA approved new drug bulletin. Gabapentin (neurontin).
RN; 1994 Jul; 57(7):39-40. PubMed ID: 8047795
[No Abstract] [Full Text] [Related]
9. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
[TBL] [Abstract][Full Text] [Related]
10. Gabapentin (Neurontin, Parke-Davis).
Fisher K; McPherson ML
Am J Hosp Palliat Care; 1997; 14(6):311-2. PubMed ID: 9392729
[No Abstract] [Full Text] [Related]
11. Gabapentin (NEURONTIN)--a novel anticonvulsant.
Murdoch LA
Axone; 1994 Dec; 16(2):56. PubMed ID: 7727298
[TBL] [Abstract][Full Text] [Related]
12. Pfizer to pay $430 million over promoting drug to doctors.
Harris G
N Y Times Web; 2004 May; ():C6. PubMed ID: 15290803
[No Abstract] [Full Text] [Related]
13. The Neurontin legacy--marketing through misinformation and manipulation.
Landefeld CS; Steinman MA
N Engl J Med; 2009 Jan; 360(2):103-6. PubMed ID: 19129523
[No Abstract] [Full Text] [Related]
14. Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.
Vedula SS; Goldman PS; Rona IJ; Greene TM; Dickersin K
Trials; 2012 Aug; 13():136. PubMed ID: 22888801
[TBL] [Abstract][Full Text] [Related]
15. [Gabapentin--a new add-on antiepileptic drug].
Vassella F
Praxis (Bern 1994); 1996 Jan; 85(4):73. PubMed ID: 8578056
[No Abstract] [Full Text] [Related]
16. Gabbing about gabapentin.
Nat Rev Drug Discov; 2003 Apr; 2(4):254. PubMed ID: 12680367
[No Abstract] [Full Text] [Related]
17. Parke-Davis whistle-blower speaks at last.
Larkin M
Lancet Neurol; 2003 May; 2(5):264. PubMed ID: 12849165
[No Abstract] [Full Text] [Related]
18. Gabapentin for seizure control in organ transplant recipients.
Warner EG
J Heart Lung Transplant; 1995; 14(5):1011. PubMed ID: 8800713
[No Abstract] [Full Text] [Related]
19. Confounding factors in off-label drug use.
Greenberg PE; Pike C; Sisitsky T
Health Aff (Millwood); 2012 Feb; 31(2):460; author reply 460. PubMed ID: 22323178
[No Abstract] [Full Text] [Related]
20. [Gabapentin--a new anti-epileptic agent].
Nervenarzt; 1994 Jun; 65(6 Suppl):1-8. PubMed ID: 9211669
[No Abstract] [Full Text] [Related]
[Next] [New Search]
